Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 15/20 | 0.75 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.75 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.75 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2133591 | 1.00 | P2RY6 (0.75) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL17211062 | 1.00 | P2RY6 (0.75) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL21277458 | 1.00 | P2RY6 (0.75) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL12714923 | 1.00 | P2RY6 (0.75) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL29515219 | 1.00 | P2RY6 (0.75) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL3026247 | 0.98 | P2RY6 (0.78) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL3026250 | 0.98 | P2RY6 (0.78) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL6823629 | 0.91 | P2RY6 (0.64) | P2RY6P2RY2P2RY4 | |
| SCHEMBL6823632 | 0.91 | P2RY6 (0.64) | P2RY6P2RY2P2RY4 | |
| SCHEMBL9796913 | 0.90 | DNPH1 (0.74) | P2RY6P2RY2P2RY4DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1621 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12460204-B2 | Artificial nucleic acid molecules for improved protein or peptide expression | CureVac SE (DE) | 2025-11-04 | — | — | US | claimed |
| US-20250210148-A1 | METHOD OF PRODUCING DATA-ENCODED NUCLEIC ACID AND NUCLEIC ACID PRODUCED BY THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-06-26 | — | — | US | claimed |
| WO-2025105506-A1 | NUCLEIC ACID, DRUG COMPOSITION, AND METHOD OF PRODUCING NUCLEIC ACID | アンジェス株式会社 | 2025-05-22 | — | — | WO | claimed |
| US-20250136711-A1 | SEMENOGELIN NEUTRALIZING ANTIBODY AND EPITOPE AND APPLICATION THEREOF | SHANGHAI BIOTROY BIOTECHNIQUE CO., LTD (CN) | 2025-05-01 | — | — | US | claimed |
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | TRANSLATE BIO INC (US) | 2024-12-19 | — | — | US | claimed |
| CN-119040364-A | Residue-free sequence cyclic RNA based on ribozyme self-splicing and preparation method thereof | 优环(苏州)生物医药科技有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-118924887-A | HPV MRNA LNP vaccine | 南京吉迈生物技术有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | TRANSLATE BIO, INC. (US) | 2024-06-04 | — | — | US | claimed |
| US-11980672-B2 | Heterologous UTR sequences for enhanced mRNA expression | MODERNATX, INC. (US) | 2024-05-14 | — | — | US | claimed |
| US-11951120-B2 | Modification of gene transcription and translation efficiency by 5′UTR sequence variation | Nanjing GeneLeap Biotechnology Co., Ltd. | 2024-04-09 | — | — | US | claimed |
| EP-0889728-B1 | METHOD OF TREATING CILIARY DYSKINESIA WITH URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS | INSPIRE PHARMACEUTICALS INC (US) | 2006-08-09 | — | — | EP | claimed |
| EP-0724647-A4 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | GILEAD SCIENCES INC (US) | 2003-09-17 | — | — | EP | claimed |
| US-20030039976-A1 | Methods for base counting | PE CORPORATION (NY) | 2003-02-27 | — | — | US | claimed |
| US-5972904-A | Method of treating sinusitis with uridine triphosphates and related compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 1999-10-26 | — | — | US | claimed |
| US-5958691-A | DETECTION OF NUCLEIC ACID LIGANDS WITH MODIFIED NUCLEOTIDE TO TARGET GROUPS, SINGLE STRAND NUCLEIC ACIDS AND PARTITIONING THE NUCLEIC ACIDS, AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | claimed |
| EP-0897301-A1 | METHOD OF TREATING OTITIS MEDIA WITH URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS | Inspire Pharmaceuticals, Inc. (US) | 1999-02-24 | — | — | EP | claimed |
| US-5660985-A | CONTACTING MIXTURE OF MODIFIED SINGLE-STRANDED NUCLEIC ACIDS WITH TARGET MOLECULE, PARTITIONING THOSE WITH INCREASED AFFINITY, AMPLIFYING TO IDENTIFY LIGANDS OF TARGET MOLECULE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-08-26 | — | — | US | claimed |
| WO-1997029756-A1 | METHOD OF TREATING OTITIS MEDIA WITH URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 1997-08-21 | — | — | WO | claimed |
| EP-0724647-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NeXstar Pharmaceuticals, Inc. (US) | 1996-08-07 | — | — | EP | claimed |
| WO-1995007364-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-03-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12460204-B2 | Artificial nucleic acid molecules for improved protein or peptide expression | RNMT, NSUN3, RNGTT | P2RY6 2967/4885P2RY2 2992/4885P2RY4 2730/4885 |
| US-11980672-B2 | Heterologous UTR sequences for enhanced mRNA expression | RNGTT, UPF1, RNMT | P2RY6 4640/4885P2RY2 4412/4885P2RY4 4672/4885 |
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | NSUN3, RNMT, TRDMT1 | P2RY6 3298/4885P2RY2 3741/4885P2RY4 4107/4885 |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | NSUN3, RNMT, TRDMT1 | P2RY6 3298/4885P2RY2 3741/4885P2RY4 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.